NTBC as palliative treatment in chronic tyrosinaemia type I

Journal of Inherited Metabolic Disease

Volumn 22, Issue 5, 1999, Pages 665-666

  Ros, J ^a,c   Vilaseca, M A ^a   Lambruschini, N ^a   Mas, A ^a   Lindstedt, S ^b   Holme, E ^b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c HOSPITAL SANT JOAN DE DÉU   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYPHENYLPYRUVATE DIOXYGENASE; ENZYME INHIBITOR; NTBC; UNCLASSIFIED DRUG;

ADULT; ARTICLE; DRUG EFFICACY; HUMAN; MALE; PALLIATIVE THERAPY; TYROSINEMIA;

4-HYDROXYPHENYLPYRUVATE DIOXYGENASE; ADOLESCENT; AMINO ACID METABOLISM, INBORN ERRORS; CHRONIC DISEASE; CYCLOHEXANONES; FATAL OUTCOME; HUMANS; MALE; NITROBENZOATES; TYROSINE;

EID: 0033000508     PISSN: 01418955     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005594416973     Document Type: Article

References (2)

1. Holme E, Lindstedt S (1998) Tyrosinemia type I and NTBC (2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione). J Inher Metab Dis 21: 507-517.
2. Lindstedt S, Holme E, Lock EA, Hjalmarsson O, Strandvik B (1992) Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase. Lancet 340: 813-817.